Mark Freedman discusses recent developments and unmet needs in MS. Part 1 of 2.
View Part 2 here.
1. What have been the most significant recent developments in MS? (0:05)
2. Discuss the current unmet needs and/or the challenges you face as an MS specialist (1:05)
Speaker disclosures: Mark Freedman has received honoraria or consultation fees from Bayer Healthcare, Biogen-Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis and Teva Canada Innovation. He is a member of the following company advisory boards, board of directors or other similar group for Bayer Healthcare, Biogen-Idec, Hoffman La-Roche, Merck Serono, Novartis, Opexa and Sanofi-Aventis. He is a participant in Genzyme’s company-sponsored speaker’s bureau.
Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.
Share this Video
Related Videos In Multiple Sclerosis
Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS
touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]
Le Hanh Hua, ECTRIMS 2021: Hot Topics in Multiple Sclerosis
touchNEUROLOGY joins Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the hot topics in the field of multiple sclerosis. The abstract entitled: ‘Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study’ was […]
Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study
It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study. The abstract entitled: ‘Safety and efficacy of siponimod in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!